Patient Perspectives on the Costs of a New Cancer Therapy

Have you been treated for blood cancer, are 18+ and a resident of Canada? If so, researchers at the Ottawa Hospital Research Institute (OHRI) would love your input about a new cancer therapy, Chimeric Antigen Receptor (CAR) T-cell therapy, that has been approved in Canada for treatment of advanced leukemia. A research study will be conducted to share perspectives from patients and family members of patients across Canada on the costs and benefits that the health care system needs to be aware of when evaluating this new blood cancer treatment. Participation includes a 2-3 hour virtual group discussion, in English, along with an online feedback form. Group sessions will begin October 20 and October 27. If you have questions or are interested in participating, please contact macwilson@ohri.ca.

CAR T-cell therapy has shown promising results with the potential to cure the disease. In developing new cancer therapies, an evaluation of the costs and benefits associated with therapy can support healthcare decision-makers to decide which therapies are funded to make the most of limited funds and improve health outcomes. Without the input of different voices, the evaluation of the cancer therapy may not reflect the perspectives and experiences of patients and their families.

Sessions will last from 12:30 to 3:30 (EDT) and additional discussions may be added if sufficient interest to do so is shown.

Following completion of the online feedback form, participants will be provided with an Amazon gift card valued at $10 as a recognition of their time and contribution.

Please note that participation in this study is voluntary and will not affect your care. If you have any questions or are interested in participating, please contact: Mackenzie Wilson, study Research Assistant (macwilson@ohri.ca; 613-737-8899 ext. 73813).